Proteasome inhibitor delanzomib for use in the treatment of lupus
US9340559B2 · kind B2 · utility
3Cited by
0References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 2, 2012 |
| Grant date | May 17, 2016 |
| Priority date | — |
| Expiry date | Nov 21, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07F5/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a method for treating lupus in a subject, comprising the step of administering to the subject Compound A.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.